Aliases & Classifications for Dysentery

MalaCards integrated aliases for Dysentery:

Name: Dysentery 12 44 15 17 72
Infectious Diarrhea 12 55 63

Classifications:



External Ids:

Disease Ontology 12 DOID:12384
ICD9CM 35 009.2
MeSH 44 D004403
SNOMED-CT 68 19213003
UMLS 72 C0013369

Summaries for Dysentery

PubMed Health : 63 About infectious diarrhea: Diarrhea is very common: In Germany, for instance, adults get it once a year on average, and it is even more common in children. It is usually caused by viruses, the most common of which are the highly contagious norovirus and rotavirus. Infectious diarrhea can also come from bacteria such as Salmonella or Campylobacter. In normal cases of diarrhea, you can usually just replace the fluids you lose and wait until the infection goes away. But more severe or longer lasting diarrhea needs to be treated because it can lead to the loss of dangerously high levels of fluid and salt, especially in young children and older people.

MalaCards based summary : Dysentery, also known as infectious diarrhea, is related to typhoid fever and intestinal disease, and has symptoms including diarrhea An important gene associated with Dysentery is ALB (Albumin), and among its related pathways/superpathways are Photodynamic therapy-induced NF-kB survival signaling and Interleukin-1 processing. The drugs Azithromycin and Simethicone have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and liver.

Disease Ontology : 12 An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood.

Wikipedia : 75 Dysentery is an inflammatory disease of the intestine, especially of the colon, which always results in... more...

Related Diseases for Dysentery

Diseases related to Dysentery via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
# Related Disease Score Top Affiliating Genes
1 typhoid fever 31.6 IL1B CRP ALB
2 intestinal disease 31.0 IL1B CRP ALB
3 gastroenteritis 31.0 IL1B CRP ALB
4 paratyphoid fever 30.8 IL1A CRP
5 abdominal tuberculosis 30.8 CRP ALB
6 meningitis 30.7 IL1B CRP ALB
7 peritonitis 30.7 IL1B CRP ALB
8 end stage renal failure 30.5 TF CRP ALB
9 appendicitis 30.5 IL1B ENO2 CRP ALB
10 uremia 30.5 TF CRP ALB
11 deficiency anemia 30.4 TF HP CRP ALB
12 parotitis 30.3 LTF ALB
13 kidney disease 30.1 TTR TF CRP ALB
14 pneumonia 30.0 IL1B CRP CD40LG
15 acquired immunodeficiency syndrome 30.0 IL1B IFNA2 ALB
16 clostridium difficile colitis 29.9 LTF IL1B
17 vasculitis 29.8 IFNA2 CRP CD40LG
18 gastrointestinal system disease 29.7 LTF IL1B CRP ALB
19 rheumatic disease 29.5 IL1B CRP CD40LG
20 glomerulonephritis 29.5 IL1B CD40LG ALB
21 malaria 28.7 TF IL1B IL1A HP CRP CD40LG
22 protozoal dysentery 12.6
23 amebiasis 12.3
24 balantidiasis 12.0
25 shigellosis 11.8
26 campylobacteriosis 11.7
27 oesophagostomiasis 11.2
28 diarrhea 11.0
29 epstein-barr virus hepatitis 10.7 TF ALB
30 paramyloidosis 10.7 TTR ALB
31 gastrointestinal tuberculosis 10.7 CRP ALB
32 acquired angioedema 10.7 HP CRP
33 folic acid deficiency anemia 10.7 TF CRP
34 yellow nail syndrome 10.6 TF ALB
35 median rhomboid glossitis 10.6 TTR TF
36 keratomalacia 10.6 TTR TF
37 colitis 10.6
38 granulomatous hepatitis 10.6 IFNA2 CRP
39 melancholia 10.6 TF HP
40 bronchus cancer 10.6 ENO2 CRP
41 salmonellosis 10.6
42 cholera 10.6
43 superficial siderosis of the central nervous system 10.5 TF LTF
44 superficial siderosis 10.5 TF LTF
45 keratoconjunctivitis 10.5
46 ulcerative colitis 10.5
47 rheumatic myocarditis 10.5 IL1A CRP
48 kwashiorkor 10.5 TTR TF ALB
49 marasmus 10.5 TTR TF ALB
50 urinary system disease 10.5 TF CRP ALB

Comorbidity relations with Dysentery via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Dysentery:



Diseases related to Dysentery

Symptoms & Phenotypes for Dysentery

UMLS symptoms related to Dysentery:


diarrhea

Drugs & Therapeutics for Dysentery

PubMed Health treatment related to Dysentery: 63

You lose fluids and electrolytes when you have diarrhea, so it is important to replace them. For acute, non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute, non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte/glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugarOne and a half level tablespoons of saltOne glass of packaged orange juice In addition to drinking fluids and using other treatments, foods or dietary supplements that have probiotic microorganisms (probiotics) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children.Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options.Antibiotics are only an option if the infection is bacterial. They can't fight viruses.

Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 447043 55185
2
Simethicone Approved Phase 4 8050-81-5
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
7
Vancomycin Approved Phase 4 1404-90-6 441141 14969
8
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Fidaxomicin Approved Phase 4 873857-62-6
11
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
12
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13 Antiparasitic Agents Phase 4
14 Cola Phase 4
15 Emollients Phase 4
16 Proton Pump Inhibitors Phase 4
17 Citrate Phase 4
18 Tubulin Modulators Phase 4
19 DMP 777 Phase 4 157341-41-8
20 Anthelmintics Phase 4
21 Piperazine citrate Phase 4
22 Antimitotic Agents Phase 4
23 Acidophilus Phase 4
24 Amoxicillin-Potassium Clavulanate Combination Phase 4
25 beta-Lactamase Inhibitors Phase 4
26 Fluoroquinolones Phase 4
27
Lactulose Approved Phase 2, Phase 3 4618-18-2 11333
28
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
29
Zinc Approved, Investigational Phase 3 7440-66-6 32051
30
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
31
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
32 Antiprotozoal Agents Phase 2, Phase 3
33 Antibodies Phase 3
34 Immunoglobulins Phase 3
35 Rifamycins Phase 3
36 rifamycin SV Phase 3
37 Antirheumatic Agents Phase 3
38 Micronutrients Phase 3
39 Nutrients Phase 3
40 Trace Elements Phase 3
41 Vitamins Phase 3
42 Antioxidants Phase 3
43 retinol Phase 3
44 Retinol palmitate Phase 3
45 Protective Agents Phase 3
46 Topoisomerase Inhibitors Phase 3
47 Bifidobacterium Phase 3
48 Antiemetics Phase 3
49 topoisomerase I inhibitors Phase 3
50 Analgesics Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults Completed NCT00807326 Phase 4 Loperamide/simeticone 2 mg/125 mg caplets;Loperamide/simeticone 2 mg/125 mg chewable tablets;Probiotic Saccharomyces boulardii 250 mg capsules
2 The Effect of a Probiotic and/or Prebiotic on the Duration of Diarrhea and Length of Hospital Stay in Children With Acute Diarrhea: Prospective, Double Blind, Randomized Controlled Trial Completed NCT01927094 Phase 4
3 The Effects of Gastric Acid Suppression on the Colonic Microbiome Completed NCT01901276 Phase 4 Omeprazole 40 mg bid
4 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
5 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
6 Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone Completed NCT00359970 Phase 4 Azithromycin 500 mg;Azithromycin 1000 mg;Loperamide
7 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases – A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
8 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial Recruiting NCT02765217 Phase 4 Lactobacillus reuteri DSM 17938;Placebo;Amoxicillin-Clavulanic Acid
9 CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection Recruiting NCT02667418 Phase 4 Fidaxomicin;Vancomycin with Taper/Pulse;Vancomycin
10 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Not yet recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
11 A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea Terminated NCT01005849 Phase 4
12 Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients Terminated NCT01972932 Phase 4
13 Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea Withdrawn NCT00875875 Phase 4 Rifaximin
14 Can Use of Bismuth Subsalicylate in Clostridium Difficile Patients Decrease the Length of Stay and Time to Resolution of Symptoms Withdrawn NCT03592082 Phase 4 Bismuth Subsalicylate;standard antibiotic therapy
15 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose
16 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
17 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in The Prevention of Acute Diarrhoeal Diseases in Children Unknown status NCT00534170 Phase 3
18 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children Completed NCT00366730 Phase 3 Nitazoxanide
19 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents Completed NCT00366236 Phase 3 Nitazoxanide
20 A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea Completed NCT00742469 Phase 3 Rifaximin;Placebo
21 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
22 Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni Completed NCT02280044 Phase 2, Phase 3
23 A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers Completed NCT01208922 Phase 3 Rifamycin SV-MMX®;Ciprofloxacin
24 Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms Completed NCT01909128 Phase 3
25 A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults. Completed NCT00737412 Phase 3
26 A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States Completed NCT00328380 Phase 3 Rifaximin
27 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea Completed NCT01142089 Phase 3 Placebo;Rifamycin SV MMX
28 Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
29 Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
30 Vitamin A Supplementation in Newborns Study Completed NCT00114868 Phase 3 Vitamin A
31 Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study Recruiting NCT02819960 Phase 3 PROBIO-FIX INUM®;Placebo
32 An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea Terminated NCT00466635 Phase 3 GT267-004 (tolevamer potassium sodium)
33 A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea Terminated NCT02920242 Phase 3 Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo
34 Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea Withdrawn NCT02736539 Phase 3 CBS 2004 (galacto-oligosaccharides);Placebo
35 A Randomized, Non-inferiority, Active Controlled Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin Versus Doxycycline in the Treatment of Plague in Humans Unknown status NCT01243437 Phase 2 ciprofloxacin;doxyxcycline
36 Probiotics for Infectious Diarrhea in Children in South India Completed NCT01130792 Phase 1, Phase 2
37 A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea Completed NCT00034294 Phase 2 GT160-246
38 A Study of the Pharmacokinetics of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea Completed NCT00382304 Phase 2 tolevamer potassium-sodium (GT267-004)
39 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults Completed NCT00751777 Phase 2
40 A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers Completed NCT00210288 Phase 2
41 A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia Completed NCT01040325 Phase 2
42 Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults Completed NCT01080716 Phase 1, Phase 2
43 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
44 A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Completed NCT02676895 Phase 2
45 Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02646371 Phase 2
46 A Randomized, Double-Blind, Single Center, Comparative Dose Ranging Study of Rifaximin Vs. Placebo in the Prevention of Travelers' Diarrhea Due to Enteropathogenic Bacteria Completed NCT00098384 Phase 2 rifaximin
47 Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study Completed NCT03447821 Phase 2 400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage
48 Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity Completed NCT02354339 Phase 2
49 Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis Completed NCT00800930 Phase 2
50 Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity Completed NCT01034228 Phase 2

Search NIH Clinical Center for Dysentery

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azithromycin
Bismuth subsalicylate
Ciprofloxacin
Ciprofloxacin
Levofloxacin
Loperamide
Norfloxacin
Ofloxacin
Rifaximin
Scopolamine
Scopolamine Hydrobromide
Sulfamethoxazole

Cochrane evidence based reviews: dysentery

Genetic Tests for Dysentery

Anatomical Context for Dysentery

MalaCards organs/tissues related to Dysentery:

41
Testes, Colon, Liver, Small Intestine, Neutrophil, Skin, Kidney

Publications for Dysentery

Articles related to Dysentery:

(show top 50) (show all 8057)
# Title Authors PMID Year
1
Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. 9 38
19028207 2008
2
Antibiotics for the empirical treatment of acute infectious diarrhea in children. 9 38
17568855 2006
3
Modelling the dynamics of direct and pathogens-induced dysentery diarrhoea epidemic with controls. 38
30843764 2019
4
Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. 38
30963783 2019
5
Glyphaea brevis - In vitro antioxidant and in silico biological activity of major constituents and molecular docking analyses. 38
30998971 2019
6
Pistacia weinmannifolia ameliorates cigarette smoke and lipopolysaccharide‑induced pulmonary inflammation by inhibiting interleukin‑8 production and NF‑κB activation. 38
31257455 2019
7
Protective effect of Shaoyao Decoction against colorectal cancer via the Keap1-Nrf2-ARE signaling pathway. 38
31146002 2019
8
A review of the pharmacological and therapeutic effects of auraptene. 38
31424600 2019
9
Dissemination of Multidrug-Resistant Shigella flexneri and Shigella sonnei with Class 1, Class 2, and Atypical Class 1 Integrons in China. 38
31369341 2019
10
Antimicrobial resistances, and molecular typing of Campylobacter jejuni isolates, separated from food-producing animals and diarrhea patients in Iran. 38
31300113 2019
11
Self-assembling Rotavirus VP6 Nanoparticle Vaccines Expressed in Escherichia coli Elicit Systemic and Mucosal Responses in Mice. 38
31429685 2019
12
Intradermal or sublingual delivery and heat-labile enterotoxin (LT) proteins shape immunologic outcomes to CFA/I fimbriae-derived subunit antigen vaccine against enterotoxigenic E. coli. 38
31427449 2019
13
Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study. 38
31172410 2019
14
Host Invasion by Pathogenic Amoebae: Epithelial Disruption by Parasite Proteins. 38
31416298 2019
15
A comparative in silico analysis of Rab5 proteins from pathogenic species to find its role in the pathogenesis. 38
31432591 2019
16
Identification of Enteropathogens by Multiplex PCR among Rural and Urban Guatemalan Children with Acute Diarrhea. 38
31392942 2019
17
Exploring the Relevance of Green Space and Epidemic Diseases Based on Panel Data in China from 2007 to 2016. 38
31319532 2019
18
Acute phase response in bovine coronavirus positive post-weaned calves with diarrhea. 38
31345246 2019
19
Draft Genome Sequences of Antimicrobial-Resistant Shigella Clinical Isolates from Pakistan. 38
31346012 2019
20
Prevalence of Shigella species and its drug resistance pattern in Ethiopia: a systematic review and meta-analysis. 38
31288806 2019
21
Evaluation of the antiulcer activity of the aqueous stem bark extract of Balanites aegyptiaca L Delile in Wistar rats. 38
31055003 2019
22
Identifying Infectious Diarrhea Hot spots and Associated Socioeconomic Factors in Anhui Province, China. 38
31333151 2019
23
Multiplex polymerase chain reaction test to diagnose infectious diarrhea in the emergency department. 38
30587396 2019
24
Spectroscopic Studies of Asparaginyl-tRNA Synthetase from Entamoeba histolytica. 38
30919766 2019
25
Association of meteorological factors with infectious diarrhea incidence in Guangzhou, southern China: A time-series study (2006-2017). 38
30954825 2019
26
Origanum majorana L. extract exhibit positive cooperative effects on the main mechanisms involved in acute infectious diarrhea. 38
30217790 2019
27
Antimotility Agents For The Treatment Of Acute Non-Infectious Diarrhea In Critically Ill Patients: A Practice Management Guideline From The Eastern Association For The Surgery Of Trauma. 38
31335752 2019
28
Probiotics for oral and vulvovaginal candidiasis: A review. 38
31112355 2019
29
Clinical Significance of Inflammatory Biomarkers in Acute Pediatric Diarrhea. 38
31338312 2019
30
The good bugs: the use of probiotics in pediatrics. 38
31356353 2019
31
Health benefits of yogurt among infants and toddlers aged 4 to 24 months: a systematic review. 38
31038676 2019
32
A time-trend ecological study for identifying flood-sensitive infectious diseases in Guangxi, China from 2005 to 2012. 38
31306984 2019
33
Complete Genome Sequence of a Novel Myoviridae Phage, SfΦ01, Infecting Shigella spp. 38
31171618 2019
34
Assessing Students' Knowledge on WASH-Related Diseases. 38
31185642 2019
35
Virulence gene profiles of Shigella species isolated from stool specimens in India: its association with clinical manifestation and antimicrobial resistance. 38
31221039 2019
36
Fluoroquinolones-resistant Shigella species in Iranian children: a meta-analysis. 38
31154582 2019
37
The impact of the 2016 flood event in Anhui Province, China on infectious diarrhea disease: An interrupted time-series study. 38
31051323 2019
38
Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFκB inhibition. 38
31101589 2019
39
Survey, characterization and antimicrobial susceptibility of Clostridium difficile from marine bivalve shellfish of North Adriatic Sea. 38
30927688 2019
40
Effects of ambient temperature on bacillary dysentery: A multi-city analysis in Anhui Province, China. 38
31186130 2019
41
An atypical weakly haemolytic strain of Brachyspira hyodysenteriae is avirulent and can be used to protect pigs from developing swine dysentery. 38
31217030 2019
42
An open-label randomized pragmatic non-inferiority pilot trial to compare the effectiveness of Dysentery compound with individualized homeopathic medicines in irritable bowel syndrome. 38
31199766 2019
43
[Episodes of nontyphoidal salmonellosis in adult patients of the Valladolid West Area in 2017: Evaluation of the suitability of the microbiological culture request and the prescribed treatment]. 38
30950256 2019
44
Therapeutic effect of Brucea javanica oil emulsion on experimental Crohn's disease in rats: Involvement of TLR4/ NF-κB signaling pathway. 38
30901719 2019
45
NMR studies of daidzein and puerarin: active anti-oxidants in traditional Chinese medicine. 38
31243583 2019
46
The impact of climate variability on infectious disease transmission in China: Current knowledge and further directions. 38
30928856 2019
47
Pathogenic Entamoeba histolytica, but not Entamoeba dispar, induce neutrophil extracellular trap (NET) formation. 38
30913315 2019
48
Pharmacognostical study of Desmodium caudatum. 38
31241702 2019
49
Target identification and intervention strategies against amebiasis. 38
31112766 2019
50
Two chromones with antimicrobial activity from the leaf latex of Aloe monticola Reynolds. 38
31137974 2019

Variations for Dysentery

Expression for Dysentery

Search GEO for disease gene expression data for Dysentery.

Pathways for Dysentery

Pathways related to Dysentery according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.6 IL1B IL1A CD40LG
2 9.8 IL1B IL1A

GO Terms for Dysentery

Cellular components related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 TTR TF LTF IL1B HP ENO2
2 extracellular region GO:0005576 9.7 TTR TF MFAP5 LTF IL1B IL1A
3 extracellular space GO:0005615 9.36 TTR TF LTF IL1B IL1A IFNA2
4 blood microparticle GO:0072562 9.33 TF HP ALB

Biological processes related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 IL1RAPL2 IL1B IL1A IFNA2
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.61 LTF IL1B CD40LG
3 cellular protein metabolic process GO:0044267 9.56 TTR TF LTF ALB
4 inflammatory response GO:0006954 9.55 IL1B IL1A IFNA2 CRP CD40LG
5 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.4 IL1B IL1A
6 ectopic germ cell programmed cell death GO:0035234 9.32 IL1B IL1A
7 retina homeostasis GO:0001895 9.13 TF LTF ALB
8 fever generation GO:0001660 8.62 IL1B IL1A

Molecular functions related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 8.96 IL1B IL1A
2 cytokine activity GO:0005125 8.92 IL1B IL1A IFNA2 CD40LG

Sources for Dysentery

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....